Long COVID is a Horizon Europe project aiming to understand the mechanisms of host-virus response behind the long-term symptoms following COVID-19 infection.

ISLET is a European project spearheaded by a unique team of scientists that share an ambitious common goal: to pioneer a new advanced cell therapy for Type 1 Diabetes. This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 874839 ISLET.

SOPHIA aims to enable healthcare professionals to reliably predict the complications of obesity and who will respond to treatment. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875534. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874753.

Lipotype GmbH is supported and receives funding by the German Federal Ministry of Education and Research and the BMBF innovation initiative “Entrepreneurial Regions” („Unternehmen Region“) for the New German Länder within the project Praemed.Bio.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115974 (Beat-DKD). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 16.0097-2.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115881 (RHAPSODY). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 16.0097-2.